Mitchell Warren – Executive Director, AVAC
AVAC is a global advocacy group focused on HIV prevention. It aims to accelerate ethical research and effective deployment of HIV prevention tools while working to ensure their equitable access.…
Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993.
Incyte has one drug, Jakafi, which has been approved by the U.S. Food and Drug Administration(FDA) and has been prescribed to several thousand patients in the United States.[3]
As of 2014 the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[4][5] It gained EU approval in February 2017.[6] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[7][8]
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck’s pembrolizumab (Keytruda) and Bristol Myers Squibb’s nivolumab (Opdivo).[9][10]
Novartis acquired Incyte’s c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma.[11]
AVAC is a global advocacy group focused on HIV prevention. It aims to accelerate ethical research and effective deployment of HIV prevention tools while working to ensure their equitable access.…
Johnson & Johnson has been building its medtech arm and creating a differentiated pipeline through strategic M&A, an approach that generated USD 30.4 billion in medical device sales last year,…
ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR), and PharmaBoardroom’s content partner, continues to monitor healthcare trends and conduct horizon scanning around the world. The “ISPOR 2024-2025 Top…
As healthcare costs are set to be a key issue for voters in the upcoming US presidential election, PhRMA’s Robert Zirkelbach lays out why policymakers must abandon partisan solutions that…
Online pharmacies have still not captured a large share of the fragmented US pharma market, but Eli Lilly’s partnership with Amazon after a direct-sale initiative of its own may serve…
The COVID-19 pandemic looked like a turning point for vaccines, but while R&D has made tremendous strides with ground-breaking platform technologies and mRNA, vaccines continue to attract fewer investments than…
Writing in the March 2024 edition of the DIA Global Forum magazine, Scott P. Commins of the University of North Carolina School of Medicine, Jasmine Uchi of VeganMed, and Sachin…
At the American trade association’s latest CEO & Investor Conference, the board chair of the Biotechnology Innovation Organization (BIO) Ted W. Love discussed US policies and speculated about the impact…
Drawing inspiration from Quentin Tarantino’s directorial breakthrough in the early 1990s, Blue Spoon Consulting’s John Singer explores the pharma sector’s urgent need for a strategic overhaul to ensure success and…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the…
In late 2023, The Wall Street Journal published the article Generic Drugs Should Be Cheap, but Insurers Are Charging Thousands of Dollars for Them. This article examined interactions between patient health insurance prescription…
US Congress has highlighted Chinese biotechnology firms, including giants WuXi and BGI, as posing a risk to the country’s national security. PharmaBoardroom takes a look at why the US is…
See our Cookie Privacy Policy Here
